Klaria Pharmaceuticals enters into agreement with FluiMed GmbH to develop Sirolimus Alginate Film for prevention of Organ Transplant Rejection. Sirolimus has an immunosuppressant function and is used to prevent the rejection of organs in Solid Organ Transplantation (SOT) procedures. However, both the efficacy and safety of Sirolimus varies greatly between individual patients.

This variability is due to how the treatment is metabolized. An Alginate Film that delivers Sirolimus directly into the blood stream via the oral mucosa would not be subject to this variability. The result would be a treatment that would make life-saving Solid Organ Transplant procedures both less dangerous and more likely to succeed.

In the first stage of the collaboration, Klaria will conduct formulation development as well as pre-clinical development to create a drug candidate that is ready to undergo clinical testing in preparation for filing with both the EMA and the FDA. As part of the agreement, Klaria will receive upfront payments of ca SEK 10 million.